The Complement System and Peptide Modulators

The complement system is a network of more than 30 soluble plasma proteins and membrane-bound regulators that act as a rapid-response arm of innate immunity. It predates adaptive immunity by several hundred million years and is conserved across vertebrates and many invertebrates. Despite the name — which dates to its historical role as a "complement" to antibody-mediated killing — the system operates largely independently, detecting and destroying pathogens within seconds to minutes of contact.

The three activation pathways

All three complement pathways converge on a shared step: the cleavage of C3 into C3a and C3b. How they reach that step differs.

Classical pathway. Initiated when the C1q recognition molecule binds to antigen-antibody complexes (IgG or IgM) on a pathogen surface. C1q activates C1r and C1s, which cleave C4 and C2 to form the C3 convertase C4b2a. This pathway links complement directly to adaptive immunity — antibody binding triggers complement amplification.

Lectin pathway. Structurally parallel to the classical pathway but triggered by pattern recognition rather than antibodies. Mannose-binding lectin (MBL) and ficolins bind carbohydrate patterns on microbial surfaces (mannose, N-acetylglucosamine), activating MBL-associated serine proteases (MASPs) that cleave C4 and C2 to form the same C3 convertase.

Alternative pathway. Constitutively active at a low level through spontaneous hydrolysis of C3 ("tick-over"). When C3b deposits on a surface lacking complement regulators — typically a pathogen — factor B binds and is cleaved by factor D, forming the alternative pathway C3 convertase C3bBb. Factor P (properdin) stabilizes this convertase. This pathway functions as a surveillance system that amplifies any initial complement activation.

The terminal pathway and membrane attack complex

Once C3b accumulates on a target surface, C5 convertases (C4b2a3b or C3bBb3b) cleave C5 into C5a and C5b. C5b initiates assembly of the membrane attack complex (MAC) by sequentially recruiting C6, C7, C8, and multiple copies of C9. The completed MAC inserts into the target membrane and forms a transmembrane pore approximately 10 nm in diameter, causing osmotic lysis.

C3a and C5a, the small cleavage fragments, function as anaphylatoxins — potent inflammatory mediators that recruit neutrophils, increase vascular permeability, and trigger mast cell degranulation. C5a is the most potent chemoattractant produced by the complement system.

Peptide interactions with complement

Several peptides studied in the research context interact with complement components or modulate complement-driven inflammation.

LL-37 and complement. The human cathelicidin LL-37 has direct interactions with complement. LL-37 can bind C1q and activate the classical pathway independently of antibodies, enhancing opsonization of bacteria. It also modulates the inflammatory response to complement activation fragments, influencing neutrophil chemotaxis triggered by C5a. This dual role — complement activator and inflammation modulator — positions LL-37 at the intersection of antimicrobial defense and immune regulation.

Thymosin alpha-1 and complement-mediated inflammation. Thymosin alpha-1 (Ta1) modulates downstream inflammatory signaling that overlaps with complement activation. Ta1 promotes dendritic cell maturation through TLR-dependent pathways, and TLR signaling cross-talks extensively with complement. In particular, complement receptor engagement on dendritic cells and macrophages amplifies cytokine production through pathways that Ta1 also modulates, suggesting convergent regulation of inflammatory tone.

KPV and NF-kB/complement crosstalk. The tripeptide KPV (Lys-Pro-Val), derived from alpha-MSH, exerts anti-inflammatory effects primarily through inhibition of NF-kB signaling. NF-kB is a downstream effector of complement receptor activation — C3a and C5a receptor signaling both feed into NF-kB-dependent transcription of pro-inflammatory cytokines. By suppressing NF-kB, KPV indirectly dampens the inflammatory amplification loop that complement activation initiates.

Complement in disease

Dysregulated complement activation contributes to a range of pathologies:

• Autoimmune disease — complement deposits in affected tissues in lupus nephritis, rheumatoid arthritis, and anti-phospholipid syndrome. Deficiency in early classical pathway components (C1q, C4, C2) paradoxically increases lupus risk, likely due to impaired clearance of apoptotic cells and immune complexes.
• Paroxysmal nocturnal hemoglobinuria (PNH) — loss of complement regulators CD55 and CD59 on red blood cells leads to uncontrolled MAC-mediated hemolysis.
• Atypical hemolytic uremic syndrome (aHUS) — mutations in complement regulators (factor H, factor I, MCP) cause uncontrolled alternative pathway activation on endothelial surfaces.
• Age-related macular degeneration — polymorphisms in complement factor H are a major genetic risk factor, implicating chronic low-grade complement activation in retinal damage.
• Sepsis and systemic inflammation — excessive complement activation during severe infection generates overwhelming levels of C5a, contributing to organ dysfunction.

Emerging peptide-based complement inhibitors

The approval of eculizumab (a monoclonal antibody targeting C5) for PNH and aHUS validated complement as a drug target. Peptide-based approaches are now under investigation as alternatives with potentially better tissue penetration, lower manufacturing cost, and tunable pharmacokinetics. Compstatin, a 13-amino-acid cyclic peptide that binds C3 and blocks its cleavage, is the most advanced peptide complement inhibitor — its derivative pegcetacoplan received FDA approval for PNH and geographic atrophy. Other peptide and peptidomimetic strategies target C5a receptor antagonism (PMX53, a cyclic hexapeptide) and factor D inhibition. These developments suggest that peptides are well-suited to modulate complement activity at multiple points in the cascade.